Scientific Directory

Thèmes de recherche développés

Publications CSM

2019

• Inhibition of the amino‐acid transporter LAT1 demonstrates anti‐neoplastic activity in medulloblastoma
  Cormerais Y, Pagnuzzi M, Schrötter S, Giuliano S, Tambutté E, Endou H, Wempe M F, Pagès G, Pouyssegur J, Picco V
  J Cell Mol Med 1-8
• New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments
  Dufies M, Grytsai O, Ronco C, Camara O, Ambrosetti D, Hagege A, Parola J, Mateo L, Ayrault M, Giuliano S, Grépin R, Lagarde N, Montes M, Auberger P, Demange L, Benhida R, Pagès G
  Theranostics 9(18): 5332–5346
• Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5
  Giuliano S, Dufies M, Ndiaye P D, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero J-M, Mograbi B, Pagès G
  Theranostics 9(4): 1181-1199
• VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
  Ndiaye P D, Dufies M, Giuliano S, Douguet L, Grépin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P, Pagès G
  Theranostics 9(3): 661-675

2018

• Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
  Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard J C, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero J M, Chamorey E, Blot-Chabaud M, Pagès G
  Theranostics 8(9): 2447-2458
• The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)
  Cormerais Y, Massard P-A, Vucetic M, Giuliano S, Tambutté E, Durivault J, Vial V, Endou H, Wempe M F, Parks S, Pouyssegur J
  J Biol Chem 293(8): 2877-2887

2017

• CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
  Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley L S, Ambrosetti D, Guyot M, Ndiaye P D, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacques A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero J M, Pagès G
  Br J Cancer 117(7): 947-953
• Structural and functional analysis of coral Hypoxia Inducible Factor
  Zoccola D, Morain J, Pagès G, Caminiti Segonds N, Giuliano S, Tambutté S, Allemand D
  PLoS ONE 12(11): e0186262
• Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.
  Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye P D, Mastri M, Moghrabi W, Cooley L S, Ettaiche M, Chamorey E, Parola J, Vial V, Lupus-Plesu M, Bernhard J C, Ravaud A, Borchiellini D, Ferrero J M, Bikfalvi A, Ebos J M, Khabar K S, Grépin R, Pagès G
  Cancer Res 77(5): 1-15

2016

• Genetic disruption of the multifunctional CD98/LAT1 complex demonstrates the key role of essential amino acid transport in the control of mTORC1 and tumor growth
  Cormerais Y, Giuliano S, Le Floch R, Front B, Durivault J, Tambutté E, Massar P-A, Rodriguez de la Ballina L, Endou H, Wempe M F, Palacin M, Parks S, Pouyssegur J
  Cancer Res 76(15): 4481-4492

2015

• Knockout of Vdac1 activates HIF through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation.
  Brahimi-Horn C M, Giuliano S, Saland E, Lacaze-Gervais S, Sheiko T, Pelletier J, Bourget I, Bost F, Féral C, Boulter E, Tauc M, Ivan M, Garmy-Susini B, Popa A, Mari B, Sarry J E, Craigen W J, Pouyssegur J, Mazure N M
  Cancer Metab 3: 8
• Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux
  Giuliano S, Cormerais Y, Dufies M, Grépin R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S, Mazure N M, Benhida R, Auberger P, Mograbi B, Pagès G
  Autophagy 11(10): 1891-1904

2014

• The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma
  Grépin R, Guyot M, Giuliano S, Pagnuzzi M, Ambrosetti D, Chamorey E, Scoazec J Y, Negrier S, Simonnet H, Pagès G
  Cancer Res 74(3): 873-883
• The ELRCXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
  Giuliano S, Guyot M, Grépin R, Pagès G
  Oncoimmunology 3: e28399